The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab

Robert Kester(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eric H. Rubin(Rutgers Cancer Institute), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sunita Zalani(Merck & Co., Inc., Rahway, NJ, USA (United States))
Drugs
November 13, 2024
10.1007/s40265-024-02111-7
Cited by 2

Related Papers

Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k